MKS St. Paulus GmbH — Clinical Trial Site

10 Registered trials

5 Currently recruiting

Organisation

MKS St. Paulus GmbH

Location

Schwerte, Germany

Identifier

ORG-100033760

Address

Goethestrasse 19, 58239, Germany

Departments

Breast Centre
Märkisches Brustzentrum
Märkisches Brustzentrum am Marienkrankenhaus Schwerte
Oncology

Clinical trials at this site (10)

Search interface

NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan+pembrolizumab vs. SoC chemotherapy in clinical st… Pending

2024-516734-35-00 triple-negative early breast cancer 5
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/… Recruiting

2025-522484-15-00 ER+/HER2- early breast cancer 5 2026-04-27
Patient-Centered Study of T-DXd in Metastatic HER2-Positive Breast Cancer with Real-Life Side Effect Management Recruiting

2025-521805-41-00 Patients with HER2-positive, locally advanced or metast 5 2026-02-18
A clinical study to evaluate the safety, efficacy, and impact on quality of life of capivasertib alongside routine endocrine treatment in pa… Recruiting

2024-511392-15-00 HR+/HER2- advanced breast cancer 5 2025-11-20
SURVIVE HERoes – A randomized Secondary Adjuvant Treatment Intervention study comparing Trastuzumab-Deruxtecan to SOC therapy in eBC Patient… Recruiting

2024-516173-76-01 HER2-positive or HER2-low (incl. ultra-low) early breas 5 2025-04-22
NeoAdjuvant study comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab treatment in low-risk, triple-negative early br… Recruiting

2023-508787-29-00 Triple-negative early breast cancer with low risk for r 4 2024-10-10
NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+… Ended

2024-514458-61-01 HER2+ early breast cancer 4 2024-02-05
A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi… Ended

2023-509242-35-00 HR+/HER2- early breast cancer 5 2020-07-23
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk… Ended

2024-515769-32-00 HR+/HER2- early breast cancer 5 2019-07-02
A Phase II study of post-operative palbociclib as an alternative to chemotherapy in older patients with localized breast cancer at high risk… Ended

2023-505223-31-00 Localized ER+ breast cancer 4 2019-06-14